{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:18:24Z","timestamp":1791429504011,"version":"4.3.3"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["Zoster-042"],"award-info":[{"award-number":["Zoster-042"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["Zoster-091"],"award-info":[{"award-number":["Zoster-091"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vaccine.2024.02.035","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T14:56:43Z","timestamp":1709132203000},"page":"2026-2035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview"],"prefix":"10.1016","volume":"42","author":[{"given":"S. Omar","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Dessart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-307X","authenticated-orcid":false,"given":"Raunak","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.02.035_b0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.02.035_b0010","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(09)70134-6","article-title":"Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment","volume":"8","author":"Gilden","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2024.02.035_b0015","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/STROKEAHA.120.030630","article-title":"Acute viral illnesses and ischemic stroke: pathophysiological considerations in the era of the COVID-19 pandemic","volume":"52","author":"Bahouth","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.vaccine.2024.02.035_b0020","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.02.035_b0025","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2024.02.035_b0040","article-title":"Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","article-title":"A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations","volume":"20","author":"Parikh","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.02.035_b0050","unstructured":"GSK. Shingrix (Summary of Product Characteristics). https:\/\/www.medicines.org.uk\/emc\/product\/12054\/smpc#about-medicine. Accessed August 17, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0055","unstructured":"GSK. Shingrix (zoster vaccine recombinant, adjuvanted), suspension for intramuscular injection. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Shingrix\/pdf\/SHINGRIX.PDF. Accessed August 17, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0060","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.02.035_b0065","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.02.035_b0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.02.035_b0075","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.035_b0080","unstructured":"Centers for Disease Control and Prevention. Adult immunization schedule by age. https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html. Accessed August 17, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0085","unstructured":"Centers for Disease Control and Prevention. Timing and spacing of immunobiologics. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/timing.html. Accessed August 17, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0090","doi-asserted-by":"crossref","first-page":"2195786","DOI":"10.1080\/21645515.2023.2195786","article-title":"Vaccine co-administration in adults: an effective way to improve vaccination coverage","volume":"19","author":"Bonanni","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0095","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2105\/AJPH.2011.300512","article-title":"Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers","volume":"102","author":"Gilchrist","year":"2012","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2024.02.035_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2011652","article-title":"Acceptability of the third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: preliminary data in a sample of Italian HCWs","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0105","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.035_b0110","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults","volume":"36","author":"Marechal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0115","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.vaccine.2019.08.001","article-title":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults agedaged \u226550 years: a randomized trial","volume":"37","author":"Strezova","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jinf.2021.12.033","article-title":"The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged aged \u226550 years: a randomized trial","volume":"84","author":"Min","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2024.02.035_b0125","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/cid\/ciad361","article-title":"No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a COVID-19 mRNA-1273 booster vaccine in adults aged 50 years and older: a randomized trial","volume":"77","author":"Naficy","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.035_b0130","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.035_b0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0140","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0145","unstructured":"GSK. Clinical study report for study 110390 (Zoster-006). https:\/\/www.gsk-studyregister.com\/en\/trial-details\/?id=110390. Accessed August 29, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0150","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.vaccine.2019.08.001","article-title":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: a randomized trial","volume":"37","author":"Strezova","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0155","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/infdis\/jiab505","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine","volume":"225","author":"Peterson","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.035_b0160","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4161\/hv.9961","article-title":"Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults","volume":"5","author":"Weston","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2024.02.035_b0165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/CVI.00436-09","volume":"17","author":"Gasparini","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2024.02.035_b0170","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1016\/j.vaccine.2018.05.051","article-title":"MenACWY-TT is immunogenic when co-administered with Tdap and AS04-HPV16\/18 in girls and young women: results from a phase III randomized trial","volume":"36","author":"Rivera","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0175","first-page":"320","article-title":"Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies","volume":"26","author":"Weigl","year":"1997","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.vaccine.2024.02.035_b0180","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4161\/21645515.2014.982998","article-title":"Adult vaccination: now is the time to realize an unfulfilled potential","volume":"11","author":"Tan","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations \u2014 United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.vaccine.2024.02.035_b0190","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1016\/j.vaccine.2018.06.044","article-title":"A report on the status of vaccination in Europe","volume":"36","author":"Sheikh","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0195","unstructured":"Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, National Health Interview Survey, 2021. Available at: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/adultvaxview\/pubs-resources\/vaccination-coverage-adults-2021.html (acccessed September 28, 2023)."},{"key":"10.1016\/j.vaccine.2024.02.035_b0200","doi-asserted-by":"crossref","first-page":"2127290","DOI":"10.1080\/21645515.2022.2127290","article-title":"Drivers of and barriers to routine adult vaccination: a systematic literature review","volume":"18","author":"Eiden","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1542\/peds.81.2.237","article-title":"Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines","volume":"81","author":"Deforest","year":"1988","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.02.035_b0210","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1542\/peds.85.4.682","volume":"85","author":"Dashefsky","year":"1990","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.02.035_b0215","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/0264-410X(91)90291-D","article-title":"Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy","volume":"9","author":"Giammanco","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.035_b0220","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00006454-199405000-00012","article-title":"Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious","volume":"13","author":"King","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.02.035_b0225","unstructured":"Centers for Disease Control and Prevention. Administering Shingrix. https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/shingrix\/administering-vaccine.html. Accessed August 17, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0230","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1080\/21645515.2015.1043501","article-title":"Safety assessment of adjuvanted vaccines: methodological considerations","volume":"11","author":"Tavares","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0235","doi-asserted-by":"crossref","first-page":"ofac011","DOI":"10.1093\/ofid\/ofac011","article-title":"Herpes zoster following recombinant zoster vaccine with or without concomitant vaccination","volume":"9","author":"Bruxvoort","year":"2022","journal-title":"Open Forum. Infect Dis"},{"key":"10.1016\/j.vaccine.2024.02.035_b0240","doi-asserted-by":"crossref","first-page":"2278362","DOI":"10.1080\/21645515.2023.2278362","article-title":"Recombinant zoster vaccine in immunocompetent and immunocompromised adults: a review of clinical studies","volume":"19","author":"Mwakingwe-Omari","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.02.035_b0245","unstructured":"ClinicalTrials.gov. Simultaneous RZV and aIIV4 vaccination. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05007041. Accessed August 29, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0250","unstructured":"ISRCTN Registry. Combining recombinant herpes zoster and influenza or COVID-19 vaccination. https:\/\/www.isrctn.com\/ISRCTN26495549. Accessed August 17, 2023."},{"key":"10.1016\/j.vaccine.2024.02.035_b0255","unstructured":"ClinicalTrials.gov. A study on safety and immune response of investigational RSV OA vaccine in combination with herpes zoster vaccine in healthy adults (RSV-OA=ADJ-020). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05966090?term=rsvpref3&draw=2&rank=8. Accessed August 29, 2023."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:41:10Z","timestamp":1714992070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0264410X24001944"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}